University of Massachusetts, Worcester
umassmed.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
286
Active
66
Phase 3
16
Total enrollment
892,310
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intra-nasal Dexmedetomidine | — | — | — | — | — | 1 | |
| Oral Midazolam | — | — | — | — | — | 1 | |
| Lumateperone | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | — | 2 | |
| Botulinum toxin | — | — | — | — | — | 1 |
Next readouts
- 2026-12
- 2027-04-05
- 2028-04-30
- 2029-03-15
Top conditions
- Obesity12
- Schizophrenia9
- Atrial Fibrillation6
- Schizoaffective Disorder6
- Smoking Cessation6
- Cardiovascular Diseases6
- Cancer6
- Type 2 Diabetes5
Frequently asked questions about University of Massachusetts, Worcester
- How many clinical trials does University of Massachusetts, Worcester have on ClinicalTrials.gov?
- University of Massachusetts, Worcester is listed as the lead sponsor on 286 clinical trials in ClinicalTrials.gov, 66 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Massachusetts, Worcester's trials are in Phase 3?
- 16 of University of Massachusetts, Worcester's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does University of Massachusetts, Worcester focus on?
- University of Massachusetts, Worcester's most-studied conditions on ClinicalTrials.gov are Obesity, Schizophrenia, Atrial Fibrillation, Schizoaffective Disorder, Smoking Cessation.
- When are University of Massachusetts, Worcester's next clinical trial readouts?
- University of Massachusetts, Worcester has 4 upcoming primary-completion readouts tracked here; the soonest is “Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia”, expected around 2026-12.